Executive cognitive functions

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)

ESRT-1 significantly improved executive cognitive function at 50-week follow-up in surgical PGY-1 residents compared to active controls, with a large effect size.

Effect: improvement; Cohen d = 0.89 (50-wk)